

# **Blepharitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034**

<https://marketpublishers.com/r/BCFEF0B28CB1EN.html>

Date: May 2024

Pages: 133

Price: US\$ 6,499.00 (Single User License)

ID: BCFEF0B28CB1EN

## **Abstracts**

The 7 major blepharitis markets reached a value of US\$ 891.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 1,294.7 Million by 2034, exhibiting a growth rate (CAGR) of 3.46% during 2024-2034.

The blepharitis market has been comprehensively analyzed in IMARC's new report titled "Blepharitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Blepharitis refers to an ocular condition in which the eyelids become red, irritated, swollen, and itchy. It is mainly caused by inflammation from blocked meibomian oil glands present at the base of each eyelash. Depending on the affected region of the eyelids, this ailment is categorized into anterior and posterior blepharitis. The common symptoms of the illness include watery and sticky eyes, itching, crusting, redness, swelling, burning or a foreign body sensation, frequent blinking, flaking of the skin around the eyes, misdirected growth, loss of eyelashes, etc. Individuals suffering from blepharitis may also experience visual impairment, such as blurred vision and photophobia. The diagnosis of the ailment is based on a review of the patient's clinical features, medical history, and eye examination. The healthcare professional may utilize a swab to collect a sample of the eyelid crust or oil to examine it for the presence of bacteria, fungi, or any other allergy.

The rising prevalence of bacterial infections due to trauma, eye surgery, immune deficiencies, etc., is primarily driving the blepharitis market. In addition to this, the escalating utilization of an antibiotic-steroid combination approach involving dexamethasone and moxifloxacin for treating blepharitis to reduce inflammation and irritation is further bolstering the market growth. Moreover, the increasing demand for intense pulsed light therapy, which involves the application of bright red-light pulses to

the eyelid skin, thereby treating clogged or blocked glands and providing symptom relief, is creating a positive outlook for the market. Additionally, numerous key players are investing in R&D activities for the launch of novel treatment alternatives to treat the root cause of blepharitis as a disease. This, in turn, is acting as a significant growth-inducing factor. Furthermore, the widespread adoption of non-pharmacological interventions, such as warm compresses and eyelid massages, since they can help relax tense muscles, loosen crusts, and improve patient outcomes, is also augmenting the market growth. Besides this, the inflating usage of microblepharoxfoliation, a painless medical procedure to gently exfoliate and remove debris around the eyelids, is expected to drive the blepharitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the blepharitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for blepharitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the blepharitis market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

## Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the blepharitis market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the blepharitis market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current blepharitis marketed drugs and late-stage pipeline drugs.

## In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

## Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

## Key Questions Answered in this Report:

Market Insights

How has the blepharitis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they

expected to perform till 2034?

What was the country-wise size of the blepharitis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the blepharitis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

## Epidemiology Insights

What is the number of prevalent cases (2018-2034) of blepharitis across the seven major markets?

What is the number of prevalent cases (2018-2034) of blepharitis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of blepharitis by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of blepharitis by type across the seven major markets?

How many patients are diagnosed (2018-2034) with blepharitis across the seven major markets?

What is the size of the blepharitis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of blepharitis?

What will be the growth rate of patients across the seven major markets?

## Blepharitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for blepharitis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the blepharitis market?

What are the key regulatory events related to the blepharitis market?

What is the structure of clinical trial landscape by status related to the blepharitis market?

What is the structure of clinical trial landscape by phase related to the blepharitis market?

What is the structure of clinical trial landscape by route of administration related to the blepharitis market?

## Contents

?1 Preface

### **2 SCOPE AND METHODOLOGY**

2.1 Objectives of the Study

2.2 Stakeholders

2.3 Data Sources

2.3.1 Primary Sources

2.3.2 Secondary Sources

2.4 Market Estimation

2.4.1 Bottom-Up Approach

2.4.2 Top-Down Approach

2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 BLEPHARITIS - INTRODUCTION**

4.1 Overview

4.2 Regulatory Process

4.3 Epidemiology (2018-2023) and Forecast (2024-2034)

4.4 Market Overview (2018-2023) and Forecast (2024-2034)

4.5 Competitive Intelligence

### **5 BLEPHARITIS - DISEASE OVERVIEW**

5.1 Introduction

5.2 Symptoms and Diagnosis

5.3 Pathophysiology

5.4 Causes and Risk Factors

5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 BLEPHARITIS - EPIDEMIOLOGY AND PATIENT POPULATION**

7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Epidemiology by Type (2018-2034)
  - 7.2.6 Diagnosed Cases (2018-2034)
  - 7.2.7 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Epidemiology by Type (2018-2034)
  - 7.3.6 Diagnosed Cases (2018-2034)
  - 7.3.7 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Epidemiology by Type (2018-2034)
  - 7.4.6 Diagnosed Cases (2018-2034)
  - 7.4.7 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Epidemiology by Type (2018-2034)
  - 7.5.6 Diagnosed Cases (2018-2034)
  - 7.5.7 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Epidemiology by Type (2018-2034)
  - 7.6.6 Diagnosed Cases (2018-2034)

- 7.6.7 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)
  - 7.7.4 Epidemiology by Gender (2018-2034)
  - 7.7.5 Epidemiology by Type (2018-2034)
  - 7.7.6 Diagnosed Cases (2018-2034)
  - 7.7.7 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Epidemiology by Type (2018-2034)
  - 7.8.6 Diagnosed Cases (2018-2034)
  - 7.8.7 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Epidemiology by Type (2018-2034)
  - 7.9.6 Diagnosed Cases (2018-2034)
  - 7.9.7 Patient Pool/Treated Cases (2018-2034)

## **8 BLEPHARITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 BLEPHARITIS - UNMET NEEDS**

## **10 BLEPHARITIS - KEY ENDPOINTS OF TREATMENT**

## **11 BLEPHARITIS - MARKETED PRODUCTS**

- 11.1 List of Blepharitis Marketed Drugs Across the Top 7 Markets



- 11.1.1 Drug Name – Company Name
  - 11.1.1.1 Drug Overview
  - 11.1.1.2 Mechanism of Action
  - 11.1.1.3 Regulatory Status
  - 11.1.1.4 Clinical Trial Results
  - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

## **12 BLEPHARITIS - PIPELINE DRUGS**

### 12.1 List of Blepharitis Pipeline Drugs Across the Top 7 Markets

- 12.1.1 TP 03 - Tarsus Pharmaceuticals
  - 12.1.1.1 Drug Overview
  - 12.1.1.2 Mechanism of Action
  - 12.1.1.3 Clinical Trial Results
  - 12.1.1.4 Safety and Efficacy
  - 12.1.1.5 Regulatory Status
- 12.1.2 NCX 4251- NicOx/Ocumension Therapeutics
  - 12.1.2.1 Drug Overview
  - 12.1.2.2 Mechanism of Action
  - 12.1.2.3 Clinical Trial Results
  - 12.1.2.4 Safety and Efficacy
  - 12.1.2.5 Regulatory Status
- 12.1.3 AXR270 - AxeroVision
  - 12.1.3.1 Drug Overview
  - 12.1.3.2 Mechanism of Action
  - 12.1.3.3 Clinical Trial Results
  - 12.1.3.4 Safety and Efficacy
  - 12.1.3.5 Regulatory Status
- 12.1.4 ISV-305 - InSite Vision
  - 12.1.4.1 Drug Overview
  - 12.1.4.2 Mechanism of Action
  - 12.1.4.3 Clinical Trial Results
  - 12.1.4.4 Safety and Efficacy
  - 12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. BLEPHARITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE**

## **DRUGS**

### **14. BLEPHARITIS – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

### **15 BLEPHARITIS - MARKET SCENARIO**

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
  - 15.2.1 Blepharitis - Market Size
    - 15.2.1.1 Market Size (2018-2023)
    - 15.2.1.2 Market Forecast (2024-2034)
  - 15.2.2 Blepharitis - Market Size by Therapies
    - 15.2.2.1 Market Size by Therapies (2018-2023)
    - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
  - 15.3.1 Blepharitis - Market Size
    - 15.3.1.1 Market Size (2018-2023)
    - 15.3.1.2 Market Forecast (2024-2034)
  - 15.3.2 Blepharitis - Market Size by Therapies
    - 15.3.2.1 Market Size by Therapies (2018-2023)
    - 15.3.2.2 Market Forecast by Therapies (2024-2034)
  - 15.3.3 Blepharitis - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Blepharitis - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Blepharitis - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Blepharitis - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Blepharitis - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)

- 15.5.2 Blepharitis - Market Size by Therapies
  - 15.5.2.1 Market Size by Therapies (2018-2023)
  - 15.5.2.2 Market Forecast by Therapies (2024-2034)
- 15.5.3 Blepharitis - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Blepharitis - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Blepharitis - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Blepharitis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Blepharitis - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Blepharitis - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Blepharitis - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Blepharitis - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Blepharitis - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Blepharitis - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Blepharitis - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Blepharitis - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Blepharitis - Access and Reimbursement Overview

## **16 BLEPHARITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 BLEPHARITIS MARKET - SWOT ANALYSIS**

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

## **18 BLEPHARITIS MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Blepharitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/BCFEF0B28CB1EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BCFEF0B28CB1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

